NasdaqGM - Nasdaq Real Time Price USD

Janux Therapeutics, Inc. (JANX)

24.04

-0.24

(-0.99%)

As of 12:13:27 PM EDT. Market Open.

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

SAN DIEGO, May 15, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer.

Business Wire 4 days ago

JANX
-0.99%
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

SAN DIEGO, May 08, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.

Business Wire 10 days ago

JANX
-0.99%
Janux commences Phase Ib studies in trial for prostate cancer treatment

Plans are also underway to begin three additional Phase Ib expansion studies focusing on different combinations and patient groups.

Clinical Trials Arena 13 days ago

JANX
-0.99%
Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential

We recently published a list of Unknown Billionaire Phill Gross’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other unknown billionaire Phill Gross’ stock picks with huge upside potential. Phillip “Phill” Gross is a seasoned investor and influential […]

Insider Monkey 14 days ago

JANX
-0.99%
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

SAN DIEGO, May 05, 2025--Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Business Wire 14 days ago

JANX
-0.99%
Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]

Insider Monkey 14 days ago

JANX
-0.99%
Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?

We recently published a list of the 12 Best Up and Coming Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Janux Therapeutics Inc. (NASDAQ:JANX) stands against other up and coming stocks to buy according to Wall Street Analysts. Tom Lee, Fundstrat managing partner, […]

Insider Monkey last month

JANX
-0.99%
Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode?

We recently published a list of 10 Best Small-Cap Stocks to Buy Before They Explode. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other best small-cap stocks to buy before they explode. Is Market Volatility Good For Small-Cap Stocks? Since the announcement of tariffs, investors […]

Insider Monkey last month

JANX
-0.99%
Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March

We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other stocks that are receiving the most insider investment in March. “The economy is strong overall and has made significant progress toward […]

Insider Monkey last month

JANX
-0.99%
We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. last month

JANX
-0.99%
Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy?

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other worst high-risk high-reward growth stocks to buy. Is the Tariff Solution Around the Corner? On March 14, Tom Lee managing partner and […]

Insider Monkey last month

JANX
-0.99%
WEX, Lamb Weston, and More Stocks See Action From Activist Investors

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Barrons.com 2 months ago

LW

JANX
-0.99%

TRS
Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Arvinas (ARVN), 924% surge in interest Janux Therapeutics (JANX), 479% surge in interest Fortress Biotech (FBIO), 440% surge in interest Dogwood Therapeutics (DWTX), 248% surge in interest Hepion Pharmaceuticals (HEPA), 219% surge in interest Tenaya Therapeutics (TNYA), 209% surge in interest Coherus BioSciences (CHRS), 185% surge in interest Aligos Thera

TipRanks 2 months ago

CHRS

PFE

ARVN
Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently

We recently compiled a list of the 10 Stocks With At Least $30 Million In Insider Spending Recently. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against the other stocks. We previously covered 10 stocks with at least $20 million in insider spending recently. Trump administration’s tariffs […]

Insider Monkey 2 months ago

JANX
-0.99%
Janux Therapeutics price target lowered to $41 from $62 at Scotiabank

Scotiabank lowered the firm’s price target on Janux Therapeutics (JANX) to $41 from $62 and keeps a Sector Perform rating on the shares. While the dose-escalation results for the company’s ongoing Phase 1 trial of JANX007 look promising, the firm does not believe all benchmarks required for establishing a competitive edge and potential pharma acquisition have been achieved, the analyst tells investors. The firm is lowering its price target to reflect a more muted outlook on JANX007 potential. Pu

TipRanks 2 months ago

JANX
-0.99%
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

SAN DIEGO, February 27, 2025--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.

Business Wire 2 months ago

JANX
-0.99%
Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against other oversold biotech stocks to buy now. Biotech Sector Performance and Challenges in 2024: Biotechnology stocks are among the most volatile in the market, […]

Insider Monkey 2 months ago

JANX
-0.99%
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

SAN DIEGO, January 24, 2025--Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Business Wire 3 months ago

JANX
-0.99%
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

SAN DIEGO, December 07, 2024--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters o

Business Wire 5 months ago

JANX
-0.99%
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO, December 05, 2024--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purcha

Business Wire 5 months ago

JANX
-0.99%

Performance Overview

Return	JANX	S&P 500 (^GSPC)
YTD	-55.10%	+1.12%
1-Year	-48.96%	+12.15%
3-Year	+124.04%	+52.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Janux Therapeutics, Inc. (JANX)

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Janux commences Phase Ib studies in trial for prostate cancer treatment

Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross’ Stock Picks with Huge Upside Potential

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?

Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode?

Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March

We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow

Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy?

WEX, Lamb Weston, and More Stocks See Action From Activist Investors

Biotech Alert: Searches spiking for these stocks today

Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently

Janux Therapeutics price target lowered to $41 from $62 at Scotiabank

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Performance Overview